3681 — Sinomab Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- HK$2.46bn
- HK$2.87bn
- CNY2.03m
Annual cashflow statement for Sinomab Bioscience, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -123 | -288 | -284 | -243 | -185 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -7.53 | 57.1 | -30.7 | 18.7 | 18.8 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -21.9 | 63.4 | -13.7 | 54.5 | 5.24 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -141 | -147 | -301 | -134 | -131 |
| Capital Expenditures | -76 | -201 | -114 | -104 | -41.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -103 | 62.9 | 33 | 6.97 | -53 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -179 | -138 | -81.4 | -96.9 | -94.5 |
| Financing Cash Flow Items | -52.7 | -4.69 | -4.99 | -8.23 | -5.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -18.8 | 57.5 | 102 | 82.3 | 73.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -390 | -247 | -220 | -139 | -142 |